主要文件

查看所有文档

C0430000

卡托普利

Name: 卡托普利
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

别名:

N-[(S)-3-巯基-2-甲基丙酰基]-L-脯氨酸

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₉H₁₅NO₃S

化学文摘社编号:

62571-86-2

分子量:

217.29

UNSPSC Code:

41116107

NACRES:

NA.24

PubChem Substance ID:

329774790

MDL number:

MFCD00168073

Beilstein/REAXYS Number:

477887

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

grade

pharmaceutical primary standard

API family

captopril

manufacturer/tradename

EDQM

mp

104-108 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O

InChI

1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7+/m1/s1

InChI key

FAKRSMQSSFJEIM-RQJHMYQMSA-N

Gene Information

human ... ACE(1636)

说明

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Captopril EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

血管紧张素转换酶抑制剂。抑制血管紧张素 II 的形成，血管紧张素 II 是生物活性多肽，可促进血管生成并增加微血管密度。

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Still not finding the right product?

Explore all of our products under 卡托普利

pictograms

GHS08

signalword

Danger

hcodes

H341,H360F

pcodes

P201 - P308 + P313

Hazard Classifications

Muta. 2 - Repr. 1B

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Bradykinin-potentiating peptides: beyond captopril.

Antonio C M Camargo et al.

Toxicon : official journal of the International Society on Toxinology, 59(4), 516-523 (2011-08-13)

The identification of novel endogenous and exogenous molecules acting in the complex mechanism of regulating the vascular tonus has always been of great interest. The discovery of bradykinin (1949) and the bradykinin-potentiating peptides (1965) had a pivotal influence in the

Captopril and angiotensin II receptor antagonist therapy in a pacing model of heart failure.

R I Ogilvie et al.

The Canadian journal of cardiology, 14(8), 1025-1033 (1998-09-17)

Twenty-four splenectomized dogs were subjected to rapid right ventricular pacing (RRVP) at 250 beats/min for five weeks. During the final three weeks, four groups six dogs were untreated or treated with captopril alone, with the angiotensin II type 1 (AT1)

Targeting the Renin-angiotensin system combined with an antioxidant is highly effective in mitigating radiation-induced lung damage.

Javed Mahmood et al.

International journal of radiation oncology, biology, physics, 89(4), 722-728 (2014-05-29)

To investigate the outcome of suppression of the renin angiotensin system using captopril combined with an antioxidant (Eukarion [EUK]-207) for mitigation of radiation-induced lung damage in rats. The thoracic cavity of female Sprague-Dawley rats was irradiated with a single dose

查看所有相关文献

全球贸易项目编号

货号	GTIN
C0430000	04061833450642